These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9377587)

  • 1. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.
    Deutsch SI; Rosse RB; Kendrick KA; Fay-McCarthy M; Collins JP; Wyatt RJ
    Clin Neuropharmacol; 1993 Dec; 16(6):518-24. PubMed ID: 9377587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
    Meskanen K; Ekelund H; Laitinen J; Neuvonen PJ; Haukka J; Panula P; Ekelund J
    J Clin Psychopharmacol; 2013 Aug; 33(4):472-8. PubMed ID: 23764683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report.
    Rosenberg PB; Rosse RB; Johri SK; Kendrick K; Fay-McCarthy M; Collins JP; Tsui LC; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1996 Jun; 19(3):276-81. PubMed ID: 8726548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.
    Rosse RB; Kendrick K; Fay-McCarthy M; Prell GD; Rosenberg P; Tsui LC; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1996 Aug; 19(4):341-8. PubMed ID: 8828997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Famotidine as an adjunct treatment of resistant schizophrenia.
    Oyewumi LK; Vollick D; Merskey H; Plumb C
    J Psychiatry Neurosci; 1994 Mar; 19(2):145-50. PubMed ID: 8204567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
    Buckley PF
    Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study.
    Stryjer R; Strous R; Bar F; Shaked G; Shiloh R; Rozencwaig S; Grupper D; Buchman N; Kotler M; Rabey JM; Weizman A
    Hum Psychopharmacol; 2004 Jul; 19(5):343-6. PubMed ID: 15252826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine in schizophrenia: onset of action within the first week of treatment.
    Small JG; Kolar MC; Kellams JJ
    Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics.
    Hicks PB; Vinogradov S; Riney SJ; Su K; Csernansky JG
    J Clin Psychopharmacol; 1989 Jun; 9(3):209-12. PubMed ID: 2567742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Famotidine in the management of schizophrenia.
    Martinez MC
    Ann Pharmacother; 1999 Jun; 33(6):742-7. PubMed ID: 10410190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.
    Rosse RB; Kendrick K; Tsui LC; Fay-McCarthy M; Collins JP; Rosenberg P; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1995 Aug; 18(4):369-74. PubMed ID: 8665550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.